Gene activity data speeds up search for anti-aging compounds
Libraries of molecules that might slow aging contain millions of candidates. Testing them all is impossible. Researchers used gene activity data to narrow the search, but also ran into the limits of that approach.
One of the biggest challenges in longevity drug discovery is scale. Even with a rough pre-selection, the space of potential compounds is enormous. One strategy gaining traction is the use of transcriptomic data: information about which genes are active in aging cells versus young cells, or in cells exposed to known life-extending interventions. If a new molecule produces a similar pattern of gene activity, it becomes a candidate for further study. The researchers used both worms and mice to explore how well these strategies actually work.
Two strategies, two shortcomings
The authors describe two main approaches. The first is the reversal strategy: find compounds that reverse the gene activity changes caused by aging. This has already led to the identification of molecules such as oridonin, which extended lifespan in yeast and mice. The second is the mimicry strategy: find compounds whose gene activity profile resembles that of known interventions like caloric restriction. Both approaches share a structural problem: they tend to rediscover the same classes of compounds, particularly inhibitors of the mTOR signalling pathway (a central regulator of cell growth and metabolism) and activators of AMPK (an energy sensor inside cells).
Not every aging change is a mistake
A deeper problem is conceptual. Not all gene activity changes that occur with aging are harmful. Some are likely compensatory responses. The reversal strategy treats every change as something to be undone, which may be counterproductive for a subset of those changes. The authors conclude that transcriptomics-guided drug discovery is a useful tool, but is unlikely to uncover genuinely novel mechanisms as long as its underlying assumptions go unexamined.
For longevity research, this is a sobering message: most molecules found through this route activate stress-response pathways that have been known for decades. They do not substantially improve on the current state of the art. The authors suggest that approaches targeting the removal of accumulated damage, rather than metabolic adjustment, hold greater promise.
Want to research this yourself? Try these search terms: transcriptomics drug discovery aging | mTOR AMPK lifespan extension | geroprotective compound screening